Related to Vertex to Receive $155M Tied to HCV Drug’s Clinical and Commercial Success in Europe

• Intercell and Romark to Combine HCV Vaccine and Antiviral Drug for Phase II Trials
  
• Valeant and Kadmon Ink Two Deals Totaling $12.5M Up Front for Chronic HCV Drugs
  
• Ariana and Bio-Rad Anchor HCV Diagnostic Collaborative
  
• EC Clears J&J’s Invega for Treating Schizoaffective Disorder
  
• Investigators Identify Prognostic Marker for Treating Hep C with Peg-Interferon and Ribavirin
  
• BMS and Pharmasset to Combine HCV Candidates in Proof-of-Concept Study
  
• Vertex Plans EU and U.S. Filing for CF Therapy This Year Following Phase III Success
  
• EC Approves Janssen’s Extended-Release Injectable Schizophrenia Drug Xeplion
  
• Phase III Study Shows Vertex Drug Significantly Boosts Lung Function in Children with CF
  
• Phase III Data Suggests IL28B Genotyping Helps Predict Response to Merck & Co.’s HCV Drug
  
• Spanish Research Consortium Taps Roche Sequencing Technology for HBV and HCV Research
  
• Transgene, ChronTech, and Inovio Partner to Take Prime-Boost HCV Vaccination into Clinic
  
• FDA Rubber-Stamps Merck’s Victrelis as Combination Therapy for Chronic Hepatitis C
  
• Roche’s Multivirus Blood-Screening Assay Achieves CE Mark
  
• Avila Advances Candidate in Deal with Clovis and Inks Separate Agreement with NIAID
  
• Pharmasset and Tibotec to Carry Out Combination Study in Chronic HCV
  
• Valeant to Buy Janssen’s Ortho Dermatologics Business for $345M
  
• Merck & Co. and Roche Go Global with Marketing for Victrelis in HCV
  
• Medivir Divests Generics Subsidiary for SEK 26M
  
• EC Clears Janssen-Cilag’s Zytig as Combination Therapy for Castration-Resistant Prostate Cancer